VKTX
Price:
$54.13
Market Cap:
$6.00B
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug...[Read more]
Industry
Biotechnology
IPO Date
2015-04-28
Stock Exchange
NASDAQ
Ticker
VKTX
According to Viking Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -15.05%. This represents a change of 224.91% compared to the average of -4.63% of the last 4 quarters.
The mean historical ROE of Viking Therapeutics, Inc. over the last ten years is -63.46%. The current -15.05% ROE has changed -76.29% with respect to the historical average. Over the past ten years (40 quarters), VKTX's ROE was at its highest in in the March 2015 quarter at 20.52%. The ROE was at its lowest in in the September 2017 quarter at -274.02%.
Average
-63.46%
Median
-25.70%
Minimum
-268.24%
Maximum
98.90%
Discovering the peaks and valleys of Viking Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 81.30%
Maximum Annual ROE = 98.90%
Minimum Annual Increase = -371.24%
Minimum Annual ROE = -268.24%
Year | ROE | Change |
---|---|---|
2023 | -24.65% | -46.83% |
2022 | -46.37% | 73.33% |
2021 | -26.75% | 81.30% |
2020 | -14.75% | 58.60% |
2019 | -9.30% | 25.54% |
2018 | -7.41% | -95.15% |
2017 | -152.83% | -16.56% |
2016 | -183.17% | -31.72% |
2015 | -268.24% | -371.24% |
2014 | 98.90% | 69.46% |
The current ROE of Viking Therapeutics, Inc. (VKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.59%
5-year avg
-24.36%
10-year avg
-63.46%
Viking Therapeutics, Inc.’s ROE is greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Akero Therapeutics, Inc. (-29.56%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than Sarepta Therapeutics, Inc. (5.17%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than PTC Therapeutics, Inc. (57.03%), greater than Axsome Therapeutics, Inc. (-174.48%), greater than ImmunoGen, Inc. (-21.97%), less than Seres Therapeutics, Inc. (313.56%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Mereo BioPharma Group plc (-63.39%), less than AVROBIO, Inc. (29.68%), greater than CohBar, Inc. (-55.32%), less than Ocean Biomedical, Inc. (567.07%), greater than Enveric Biosciences, Inc. (-234.16%), greater than Elevation Oncology, Inc. (-57.97%),
Company | ROE | Market cap |
---|---|---|
-78.24% | $794.69M | |
-39.58% | $549.60M | |
-29.56% | $1.83B | |
19.32% | $6.57B | |
-95.61% | $5.30B | |
5.17% | $12.29B | |
-328.66% | $4.20M | |
57.03% | $2.43B | |
-174.48% | $4.47B | |
-21.97% | $8.73B | |
313.56% | $145.36M | |
-122.70% | $1.25B | |
32.93% | $109.78M | |
-68.93% | $312.42M | |
-24.63% | $133.38M | |
-63.39% | $664.26M | |
29.68% | $5.24M | |
-55.32% | $1.25M | |
567.07% | $33.96M | |
-234.16% | $4.53M | |
-57.97% | $36.94M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viking Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Viking Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Viking Therapeutics, Inc.'s ROE?
How is the ROE calculated for Viking Therapeutics, Inc. (VKTX)?
What is the highest ROE for Viking Therapeutics, Inc. (VKTX)?
What is the 3-year average ROE for Viking Therapeutics, Inc. (VKTX)?
What is the 5-year average ROE for Viking Therapeutics, Inc. (VKTX)?
How does the current ROE for Viking Therapeutics, Inc. (VKTX) compare to its historical average?